Efficacy of DSIP to normalize sleep in middle-aged and elderly chronic insomniacs
Schneider-Helmert D
European Neurology (1986) · n=18
18 chronic-insomnia patients across two age strata; middle-aged subjects (29–59) reached normal sleep values by end of one week of DSIP dosing, while elderly subjects (60–83) required the post-treatment follow-up week to achieve the same normalisation — an age-dependent response curve unique in the DSIP literature.
This 1986 European Neurology paper by Schneider-Helmert is the companion to his 1987 chronic-insomnia trial (Schneider-Helmert 1987) and the single best demonstration of an age-dependent response pattern for DSIP. The investigator enrolled 18 chronic psychophysiological insomniacs and stratified them into two age groups — middle-aged (29–59 years) and elderly (60–83 years). Both groups received six doses of 30 nmol/kg DSIP intravenously across one week under sleep-laboratory polysomnographic monitoring, with a one-week post-treatment follow-up. Middle-aged subjects reached normalised sleep values (sleep efficiency, sleep-onset latency, slow-wave sleep) by the end of the treatment week and maintained those values through the follow-up period. The elderly group, who began the trial with sleep disturbance approximately twice as severe as the middle-aged cohort, showed larger immediate improvements but required the full follow-up week to reach the same normalisation point — a sustained-and-progressive recovery curve rather than an acute pharmacological-response curve. Regression analysis showed that the response to DSIP correlated with baseline sleep-disturbance severity independent of the age-baseline interaction. The entire 18-patient sample reached normal sleep patterns by the end of the follow-up period.
This is an 18-patient open-label / single-group sleep-laboratory study, not a placebo-controlled trial — the 1987 paper that followed used a placebo-controlled design with smaller sample size and provides the harder evidence. The "delayed normalisation" framing in the elderly is consistent with the response pattern but the 18-patient sample is small for any subgroup-by-baseline interaction analysis. The intravenous-administration route, single-investigator setting, and 1986 polysomnographic-scoring conventions all limit how directly findings translate to modern sleep-medicine practice. The receptor mechanism through which DSIP produces its effects has not been identified (and remains unidentified four decades later) — meaning even striking response patterns sit on an incompletely characterised molecular basis. Independent replication outside the Schneider-Helmert programme is sparse; the molecule did not advance to a major industry-led clinical-development programme for insomnia indications after this period of European trial activity.
07·Member discussion
No member discussion yet.
Member-only conversation lives here — cycle notes, practitioner commentary, pattern-matching. Be the first paying member to start the thread.